Moderna, a pioneer in mRNA medicine, has achieved a significant milestone with the European Commission’s approval of their updated COVID-19 vaccine, Spikevax®, specifically designed to target the SARS-CoV-2 variant LP.8.1. This approval allows for active immunization in individuals six months of age and older, offering crucial protection against COVID-19. Following the Positive Opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), this authorization is valid across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.
With doses set to be available for eligible populations ahead of the upcoming vaccination season, Moderna continues to lead the way in combating the global impact of COVID-19. CEO Stéphane Bancel emphasizes the importance of staying protected against evolving strains and urges individuals to consult their healthcare providers regarding the updated vaccine. Leveraging their mRNA platform, Moderna is revolutionizing the landscape of medicine, swiftly developing innovative therapeutics and vaccines for a range of diseases. With a dedication to transforming human health, Moderna’s commitment to mRNA technology is paving the way for a healthier future.
Read more on usatoday.com